Targeted inactivation of EPS8 using dendrimer-mediated delivery of RNA interference. Int J Pharm 2019 Feb 25;557:178-181
Date
01/01/2019Pubmed ID
30597261Pubmed Central ID
PMC10629616DOI
10.1016/j.ijpharm.2018.12.060Scopus ID
2-s2.0-85059532457 (requires institutional sign-in at Scopus site) 6 CitationsAbstract
We developed polyamidoamine dendrimers conjugated with epidermal growth factor (EGF) for use in receptor-mediated delivery of therapeutics to cancer cells. Here, we demonstrate the utility of this approach to inhibit proliferation and migration of head and neck squamous carcinoma cells through targeting of EPS8, a key regulator of squamous carcinoma growth and motility. Use of EGF-dendrimers to deliver siRNA or shRNA against EPS8 resulted in inhibition of cell growth and reduction in cell motility. Moreover, more profound repression of the target protein was obtained with repeat exposure to the targeting reagent, and was consistent with the altered biological properties. Thus, targeting of EPS8 can be achieved with EGF-conjugated dendrimers delivering EPS8-specific RNAi therapeutics, leading to a reduction in the malignant phenotype of cells.
Author List
Yuan Q, Yeudall WA, Lee E, Yang HAuthor
Hu Yang PhD Chair, Professor in the Biomedical Engineering department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Adaptor Proteins, Signal TransducingCell Line, Tumor
Cell Movement
Dendrimers
Humans
RNA Interference
RNA, Small Interfering
